Daniel Hollenbach is a seasoned professional with over 15 years of experience in the biotech industry, currently serving as the Lead Process Engineer at Bayer Pharmaceuticals. In this pivotal role within the Platform Engineering and Automation team, Daniel is at the forefront of designing and...
Daniel Hollenbach is a seasoned professional with over 15 years of experience in the biotech industry, currently serving as the Lead Process Engineer at Bayer Pharmaceuticals. In this pivotal role within the Platform Engineering and Automation team, Daniel is at the forefront of designing and commissioning a state-of-the-art cell and gene therapy manufacturing facility on the Berkeley campus. His diverse background, which spans validation engineering, process engineering, automation, and project management, equips him with a unique perspective on the complexities of biopharmaceutical development.
Daniel's expertise in aseptic processing and Good Manufacturing Practices (GMP) is critical as he leads a talented team of process engineers through the intricacies of developing robust manufacturing processes that meet stringent FDA regulations. He is passionate about process optimization and employs root cause analysis to troubleshoot and enhance operational efficiencies. His commitment to quality systems and computer system validation ensures that all processes adhere to the highest standards of compliance and safety.
Currently, Daniel is spearheading key projects that focus on integrating innovative technologies into the manufacturing workflow, thereby streamlining production and improving yield in cell therapy applications. His ability to wear multiple hats allows him to navigate the challenges of cross-functional collaboration, ensuring that engineering solutions are not only effective but also aligned with the strategic goals of Bayer Pharmaceuticals. With a keen interest in continuous learning and adaptation, Daniel remains dedicated to advancing the field of biotechnology, making significant contributions to the future of cell and gene therapies.
